Volume 5, Issue 1, March 2020, Page: 6-8
Effect of Risk Management in Diabetic Retinopathy
Junnan Lin, Department of Ophthalmology and Stomatology, The First Affiliated Hospital of Jinan University, Guangzhou, China
Ye Li, Department of Ophthalmology and Stomatology, The First Affiliated Hospital of Jinan University, Guangzhou, China
Lishi Luo, Ophthalmology Department, The First Affiliated Hospital of Jinan University, Guangzhou, China
Received: Dec. 28, 2019;       Accepted: Jan. 6, 2020;       Published: Jan. 21, 2020
DOI: 10.11648/j.ijde.20200501.12      View  425      Downloads  108
Abstract
Objective: To evaluate the effect of risk management of nursing in diabetic retinopathy patient. Methods: 98 patients diagnosed as diabetic retinopathy from January 2018 to January 2019, they were randomly assigned to control group and intervention group, we use the different nursing measure to both of groups. Our researchers collected the data of negative patient reaction and result of serum inflammatory cytokines in before treatment and after treatment. Additionally, we collected the information associated with quality of life on participants by the short form-36 (SF-36). Result: The results of intervention group were better than the results of control group in negative patient reaction [n (%), 1 (2.0%) vs 6 (12.2%), p < 0.005]. In addition, the serum inflammatory cytokines and quality of life were improved after treatment, the improvements of intervention group were better than outcome of control group, most result of them had statistical significance (p < 0.005). Conclusion: The risk management of nursing improved the outcome of diabetic retinopathy treatment. Although improvement of negative patient reaction was non-significant in result, other aspect of patient had significantly improvement which were serum inflammatory cytokines and quality of life.
Keywords
Diabetic Retinopathy, Risk Management, Nursing
To cite this article
Junnan Lin, Ye Li, Lishi Luo, Effect of Risk Management in Diabetic Retinopathy, International Journal of Diabetes and Endocrinology. Vol. 5, No. 1, 2020, pp. 6-8. doi: 10.11648/j.ijde.20200501.12
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
American Diabetes Association. Standards of medical care in diabetes 2018. January, vol. 41; 2018. Suppl. 1.
[2]
Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet Lond Engl. 2017, 389, 10085, 2239–2251.
[3]
International Diabetes Federation. IDF Diabetes Atlas, 8th ed. Brussels. Belgium: International Diabetes Federation. 2017.
[4]
wanga FS, Njelekela MA, Diamond MB, et al. Urban and rural prevalence of diabetes and pre-diabetes and risk factors associated with diabetes in Tanzania and Uganda. Glob Health Action. 2016, 23 (9), 31440.
[5]
Agarwal P, Jindal A, Sainiv K, Jindal S. Advances in diabetic retinopathy [J]. Indian J Endoainol Metab, 2014, 18 (6), 772-777.
[6]
Sayin N, Kara N, Pekel G. Ocular complications of diabetes mellitus. World J Diabetes. 2015, 6 (1), 92-108.
[7]
Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA, J Am Med Assoc. 2007, 298 (8), 902-916.
[8]
Singh R, Ramasamy K, Abraham C, et al. Diabetic retinopathy: an update. Indian J Ophthalmol. 2008, 56 (3), 178-188.
[9]
National Eye Institute. Diabetic retinopathy. https://nei.nih.gov/eyedata/diabetic. Accessed 15 July 2017.
[10]
Takahashi H, Tampo H, Arai Y, Inoue Y, Kawashima H. Applying artificial intelligence to disease staging: deep learning for improved staging of diabetic retinopathy. PLoS One. 2017, 12, 87-90.
[11]
Solomon SD, Chew E, Duh EJ, Sobrin L, Sun JK, VanderBeek BL, et al. Diabetic retinopathy: a position statement by the American Diabetes Association. Diabetes Care. 2017, 40, 412-418.
[12]
Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology. 2015, 122, 367-74.
[13]
Ware JE. SF-36 health survey update. Spine. 2000, 25, 3130–3139.
[14]
Jorge R, Costa RA, Comt DC, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE Study). Retina. 2006, 26, 1006-1013.
[15]
Malaguarnera G, Gagliano C, Bucolo C, et al. Lipoprotein (a) in cardiovascular diseases. BioMed Res Int. 2013, 1-5.
[16]
Tan GS, Gan A, Sabanayagam C, et al. Ethnic differences in the prevalence and risk factors of diabetic retinopathy: the singapore epidemiology of eye diseases study. Ophthalmology. 2018, 125 (4), 529–536.
[17]
Tomita M, Kabeya Y, Okisugi M, Katsuki T, Oikawa Y, Atsumi Y, et al. Diabetic microangiopathy is an independent predictor of incident diabetic foot ulcer. J Diabet Res. 2016, 5938540.
Browse journals by subject